TG Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $141,148 | $120,856 | $108,185 | $83,879 |
Gross Profit | 122,210 | 105,315 | 92,786 | 74,538 |
EBITDA | 37,636 | 12,281 | 32,074 | 15,100 |
EBIT | 37,577 | 12,225 | 32,012 | 15,036 |
Net Income | 28,187 | 5,060 | 23,331 | 3,880 |
Net Change In Cash | 141,148 | 120,856 | 108,185 | 83,879 |
Free Cash Flow | 7,394 | -28,740 | -25,662 | -12,229 |
Cash | 129,126 | 132,139 | 179,894 | 195,822 |
Basic Shares | 162,559 | 162,769 | 160,244 | 160,714 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $329,004 | $233,662 | $2,785 | $6,689 |
Gross Profit | 290,518 | 219,531 | 2,520 | 5,899 |
EBITDA | 49,902 | 26,100 | -187,629 | -341,969 |
EBIT | 49,622 | 25,677 | -188,144 | -342,463 |
Net Income | 23,383 | 12,672 | -198,335 | -348,101 |
Net Change In Cash | 329,004 | 233,662 | 2,785 | 6,689 |
Cost of Revenue | -196,574 | -254,547 | ||
Free Cash Flow | -40,562 | -31,413 | -176,184 | -296,035 |
Cash | 179,894 | 92,933 | 102,304 | 298,887 |
Basic Shares | 160,336 | 148,508 | 135,411 | 132,222 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.17 |
2025-03-31 | $0.03 |
2024-12-31 | $0.15 |
